Back to all news
US EquitiesPharmaEarningsBiotech

Amylyx Soars Over 60% as Biotech Outliers Defy U.S. Market Pullback

Published on August 19, 2026

Amylyx Pharmaceuticals has emerged as one of the most striking U.S. equity moves of the week, with shares surging more than 60% in a single session and nearly tripling year to date, according to Trefis. The biotech’s rally comes as broader U.S. benchmarks retreat under pressure from higher yields, highlighting how pockets of healthcare and growth stocks are breaking away from the broader market’s pullback.

Traders watch a screen showing sharp gains in a biotech stock amid a broadly weaker U.S. equity market

Amylyx Rockets as Biotech Risers Dominate a Choppy U.S. Tape

A powerful rally in Amylyx Pharmaceuticals shares has emerged as one of the most striking U.S. equity moves of the week, with the small‑cap biotech leading a cluster of high‑beta gainers even as broader benchmarks struggle.

According to a recent rundown of market outliers from Trefis, Amylyx Pharmaceuticals (ticker AMLX) was the strongest stock in its coverage universe on August 19, logging a 63.8% one‑day return. The same report shows the stock up 190.6% year to date, catapulting the name into the top tier of 2026 biotech performers.

The outsized move came against a difficult backdrop for growth shares. Major U.S. equity indexes have retreated in recent sessions as higher Treasury yields and elevated oil prices pressured risk assets, with tech and other long‑duration stocks bearing the brunt of the selling. A separate market update from Saxo Bank noted that the S&P 500, Dow and Nasdaq 100 all fell on August 18 as yields climbed, while megacap growth names such as Microsoft and Meta dropped sharply, and Constellation Brands slumped after Berkshire Hathaway disclosed it had exited the position.

Biotech and small caps steal the spotlight

The same Trefis screen that highlighted Amylyx shows a broad swath of smaller healthcare and growth names crowding the top of the performance table.

On August 19:

  • Weave Communications (ticker WEAV) advanced 31.6%, trimming what Trefis describes as a modest year‑to‑date loss.
  • AVITA Medical (ticker RCEL) rose 24.7%, pushing its year‑to‑date gain to 185.5%.
  • Orchestra BioMed (ticker OBIO) gained 19.9%, while Lyell Immunopharma (ticker LYEL) climbed 16.5% despite remaining sharply lower on the year.
  • Haemonetics (ticker HAE) added 15.9%, and Cardinal Infrastructure (ticker CDNL) rose 15.1%.

Extending the window to five trading days, Amylyx remains prominent. Over that span, the stock delivered a 48.6% gain, ranking it among the strongest names in the group, according to the same Trefis analysis. The top of the five‑day leaderboard is dominated by healthcare and related plays such as Capricor Therapeutics (ticker CAPR), Accelerant (ticker ARX), HeartFlow (ticker HTFL) and Eton Pharmaceuticals (ticker ETON), each posting double‑digit gains over the period.

The report does not detail stock‑specific catalysts for Amylyx or its peers, but the magnitude and clustering of moves underscore how pockets of the biotech and health‑tech complex are decoupling from the broader market’s recent weakness.

Broader market context

While these names surged, major benchmarks have come under pressure.

A live market blog from MarketWatch reported that U.S. stock indexes fell for a third straight session on August 18 as semiconductor shares slumped and Treasury yields hovered near multiyear highs, with tech stocks dragging down the S&P 500.

Zacks, in a separate wrap‑up of the same period, noted that the S&P 500 declined by 53.3 points, or 0.7%, to close at 7,691.76 on August 19, framing the biotech moves against a market that has been tilting lower as investors reassess the path of interest rates and digest a maturing earnings season. The Zacks commentary also highlighted idiosyncratic movers such as H World Group Limited (ticker HTHT), whose shares jumped 11.3% after an earnings beat, and Space Exploration Technologies Corp. (ticker SPCX), which climbed 4.5% ahead of an upcoming share unlock, illustrating how stock‑specific narratives are cutting through a macro‑driven tape.

What to watch

  • Whether Amylyx Pharmaceuticals can sustain its recent 63.8% one‑day gain and triple‑digit year‑to‑date advance, or if profit‑taking emerges as broader markets remain volatile.
  • Additional disclosures from Amylyx and other top movers such as Weave Communications, AVITA Medical and Orchestra BioMed that could clarify the drivers behind their latest rallies.
  • The interaction between rising yields and high‑beta healthcare and growth names, particularly if pressure on the S&P 500 and Nasdaq persists.
  • Upcoming earnings and corporate events for companies like H World Group and Space Exploration Technologies Corp., which have already reacted sharply to recent news, potentially adding to stock‑specific dispersion in U.S. equities.

Tickers

AMLXWEAVRCELOBIOLYELHAECDNLCAPRARXHTFLETONHTHTSPCX

Sources